Drug Trial Radar · NCT04083534
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Sep 26, 2019
Primary completion
May 1, 2025
Study completion May 1, 2025
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Sep 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In the phase 1 portion of the study, the primary objectives are to assess the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine a recommended phase 2 dose regimen (RP2DR) of REGN5459 as monotherapy in patients with relapsed or refractory multiple myeloma (MM) who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit. In the phase 2 portion of the study, the primary objective is to assess the preliminary anti-tumor activity of REGN5459 as measured by objective response rate (ORR). In the phase 1 and phase 2 portion, the secondary objectives of the study are: * To assess the preliminary anti-tumor activity of REGN5459 as measured by duration of response (DOR), progression-free survival (PFS), rate of minimal residual disease (MRD) negative status, and overall survival (OS) * To evaluate the pharmacokinetic (PK) properties of REGN5459 * To characterize the immunogenicity of REGN5459 * To evaluate the effects of REGN5459 on patient-reported quality of life (QoL), symptoms, functioning and general health status In the phase 1 portion of the study only, the secondary objective of the study is to assess the preliminary anti-tumor activity of REGN5459 as measured by ORR. In the phase 2 portion of the study only, the secondary objective of the study is to evaluate the safety and tolerability of REGN5459.
Conditions
- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma
Interventions
REGN5459Drug
Administered by intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation periodTime frame: Up to 35 Days
- Incidence and severity of treatment-emergent adverse events (TEAEs) during REGN5459 treatment periodTime frame: Up to 12 Weeks After the Last Dose
- Incidence and severity of adverse events of special interest (AESI) with REGN5459 treatment periodTime frame: Up to 12 Weeks After the Last Dose
- Objective response rate (ORR) as measured using the International Myeloma Working Group (IMWG) criteriaTime frame: Up to Approximately 104 Weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Regeneron Study Site
Indianapolis, Indiana
Regeneron Study Site
Ann Arbor, Michigan
Regeneron Study Site
Rochester, Minnesota
Regeneron Study Site
New York, New York
Regeneron Study Site
Dallas, Texas
Regeneron Study Site
Houston, Texas
Regeneron Study Site
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.